RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cynata Therapeutics Stock

Cynata Therapeutics Stocks 2024

Cynata Therapeutics Stocks

179.63 M

Ticker

CYP.AX

ISIN

AU000000CYP7

WKN

A1W8VE

In 2024, Cynata Therapeutics had 179.63 M outstanding stocks, a 23.81% change from the 145.09 M stocks in the previous year.

The Cynata Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
2026e179.63
2025e179.63
2024179.63
2023145.09
2022143.28
2021130.43
2020104.82
2019100.21
201890.88
201780.3
201672.66
201560.62
201423.54
201323.54
20129.52
20115.62
20104.24
20093.75
20083.17
20073.75

Cynata Therapeutics shares outstanding

The number of shares was Cynata Therapeutics in 2023 — This indicates how many shares 145.092 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cynata Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cynata Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cynata Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cynata Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cynata Therapeutics Aktienanalyse

What does Cynata Therapeutics do?

Cynata Therapeutics Ltd is a biotechnology company focused on the development of novel stem cell therapies. The company was founded in 2011 and is headquartered in Melbourne, Australia. The founders of Cynata Therapeutics were searching for a more effective type of stem cell therapy that would surpass the limitations of existing technologies. They developed a method to generate an unlimited number of stem cells from foreign sources, making them largely immunologically neutral. These stem cells are called Cymerus stem cells and are at the core of Cynata Therapeutics' business model. In January 2015, the company went public and raised $8 million to further advance its research and development. Today, Cynata Therapeutics has branches in Australia and the USA and employs over 20 people. The business model of Cynata Therapeutics is based on manufacturing and marketing stem cell therapies using the Cymerus technology. The company's stem cell products aim to treat a wide range of diseases and injuries, including heart disease, kidney disease, neurological disorders, and various types of cancer. One of the key sectors of Cynata Therapeutics is clinical research. The company is currently conducting several clinical trials to investigate the efficacy of its stem cell therapies. For example, a recently completed study examined the use of Cymerus stem cells to treat graft-versus-host disease (GVHD), a potentially life-threatening complication that can occur after a bone marrow transplant. Cynata Therapeutics also collaborates closely with other companies and organizations in the biotechnology industry to further develop and market its technologies and therapies. In 2017, the company signed a strategic partnership with Fujifilm Cells Co. Ltd., a subsidiary of Fujifilm. One of Cynata Therapeutics' most well-known products is currently a stem cell therapy called CYP-001. This product aims to treat the physical and functional impairments that can occur after a heart attack. The therapy consists of Cymerus stem cells injected into the damaged heart tissue to repair diseased cells and rebuild the heart. Cynata Therapeutics is also committed to expanding its technologies and therapies worldwide. The company is currently working to market its products and services in Europe and Asia and has already formed distribution partnerships in several countries. Although Cynata Therapeutics is still in the early stages of its business development, it has the potential to become a leading player in the field of stem cell therapy. Through its innovative technologies and extensive clinical research activities, the company has managed to attract a growing number of customers and investors who believe that its products and services could have significant impacts on the healthcare industry. Cynata Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Cynata Therapeutics's Shares Outstanding

Cynata Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Cynata Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Cynata Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Cynata Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Cynata Therapeutics stock

How many stocks are there of Cynata Therapeutics?

The current number of stocks of Cynata Therapeutics is 179.63 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Cynata Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Cynata Therapeutics evolved in recent years?

The number of shares of Cynata Therapeutics has increased by 23.81% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Cynata Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Cynata Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Cynata Therapeutics pay?

Over the past 12 months, Cynata Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cynata Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Cynata Therapeutics?

The current dividend yield of Cynata Therapeutics is .

When does Cynata Therapeutics pay dividends?

Cynata Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cynata Therapeutics?

Cynata Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cynata Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cynata Therapeutics located?

Cynata Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cynata Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cynata Therapeutics from 11/1/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Cynata Therapeutics pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Cynata Therapeutics in the year 2023?

In the year 2023, Cynata Therapeutics distributed 0 AUD as dividends.

In which currency does Cynata Therapeutics pay out the dividend?

The dividends of Cynata Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cynata Therapeutics

Our stock analysis for Cynata Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cynata Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.